Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949356 | 0.87 | GPR119 (0.54) | HTR2AHTR6HTR2BGPR119STS | |
| SCHEMBL27986723 | 0.87 | HTR6 (0.51) | HTR2AHTR6HTR2B | |
| SCHEMBL946338 | 0.86 | HTR6 (0.53) | HTR2AHTR6HTR2B | |
| SCHEMBL951512 | 0.82 | HTR2A (0.48) | HTR2AHTR6HTR2BGPR119SFRP1 | |
| Tert-Butyl Formate SCHEMBL27986724 | 0.78 | HTR6 (0.44) | HTR2AHTR6HTR2B | |
| SCHEMBL949399 | 0.77 | HTR6 (0.60) | HTR2AHTR6HTR2BSFRP1 | |
| SCHEMBL949296 | 0.77 | HTR6 (0.50) | HTR2AHTR6HTR2BSCN9A | |
| SCHEMBL19284734 | 0.76 | GPR119 (0.54) | GPR119 | |
| SCHEMBL2197307 | 0.75 | HTR2A (0.63) | HTR2AHTR6GPR119SFRP1PIK3CA | |
| SCHEMBL947861 | 0.75 | HTR2A (0.51) | HTR2AHTR6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242102-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-08-14 | — | — | US | disclosed |
| EP-2139880-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2139880-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116831-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR2C, HTR3B, HTR1B | HTR2A 5/4885HTR6 6/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.